SGIOF

Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of -38.46% and +5.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Shionogi reported a series of positive IDWeek 2026 updates, including Phase 3 data for XOCOVA in COVID-19 post-exposure prophylaxis, new U.S. and global evidence for Fetroja in resistant Gram-negative infections, and non-inferiority Phase 3 results for oral…

OSAKA, Japan, October 21, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an…

Patients treated with Shionogi & F2G’s invasive aspergillosis drug were released from hospital sooner than those in the comparator arm.

Shionogi & Co. (SGIOY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Shionogi has delivered a solid share price gain over the past few years, helped recently by a high profile rare disease acquisition, which leaves a clear question for you as an investor: Is the current share price properly supported by the earnings the…

Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.

The Japanese drugmaker will gain global rights to Aqneursa, a drug approved in the U.S. and E.U. for two inherited neurological disorders

The acquisition of Texas-based IntraBio adds to a growing rare disease business for Shionogi by handing the company a marketed treatment for two inherited conditions.

OSAKA, Japan, October 05, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on October 5, 2026, approved Shionogi entering into…